Alacepril (BioDeep_00000765998)

   


代谢物信息卡片


1-[3-(Acetylsulfanyl)-2-methylpropanoyl]prolylphenylalanine

化学式: C20H26N2O5S (406.15623460000006)
中文名称: 阿拉普利
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(CSC(=O)C)C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)O
InChI: InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)

描述信息

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

同义名列表

2 个代谢物同义名

Alacepril; 1-[3-(Acetylsulfanyl)-2-methylpropanoyl]prolylphenylalanine



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • José L Miguel-Carrasco, Sonia Zambrano, Antonio J Blanca, Alfonso Mate, Carmen M Vázquez. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. Journal of inflammation (London, England). 2010 May; 7(?):21. doi: 10.1186/1476-9255-7-21. [PMID: 20462420]
  • Patrick B Mark, Arthur Doyle, Kevin G Blyth, Rajan K Patel, Robin A P Weir, Tracey Steedman, John E Foster, Henry J Dargie, Alan G Jardine. Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. 2008 Aug; 10(?):39. doi: 10.1186/1532-429x-10-39. [PMID: 18706114]
  • Hiroshi Nonoguchi, Shigeru Kiyama, Kenichiro Kitamura, Masahiro Naruse, Masao Tomita, Noboru Tazoe, Munemasa Tajiri, Yushi Nakayama, Yukimasa Kohda, Takeaki Inoue, Kimio Tomita. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure. Hypertension research : official journal of the Japanese Society of Hypertension. 2008 Jan; 31(1):29-36. doi: 10.1291/hypres.31.29. [PMID: 18360015]
  • Hisao Ando, Kazunori Furugori, Daijiro Shibata, Toko Harata, Yasutaka Murata, Shigehiko Mizutani. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Human reproduction (Oxford, England). 2003 Jun; 18(6):1219-22. doi: 10.1093/humrep/deg268. [PMID: 12773449]
  • Toru Kinugawa, Shuichi Osaki, Masahiko Kato, Kazuhide Ogino, Masaki Shimoyama, Yoko Tomikura, Osamu Igawa, Ichiro Hisatome, Chiaki Shigemasa. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Clinical and experimental pharmacology & physiology. 2002 Dec; 29(12):1060-5. doi: 10.1046/j.1440-1681.2002.03779.x. [PMID: 12390293]
  • A Ohtahara, I Hisatome, Y Yamamoto, M Furuse, K Sonoyama, Y Furuse, T Hamada, M Katoh, M Watanabe, T Kinugawa, K Ogino, O Igawa, T Shimomura, F Murakami, T Yamamoto, C Shigemasa. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. Journal of hypertension. 2001 Mar; 19(3 Pt 2):575-82. doi: 10.1097/00004872-200103001-00009. [PMID: 11327632]
  • K Atarashi, M Takagi, M Minami, A Ishiyama. Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats. Journal of hypertension. 1999 Dec; 17(12 Pt 2):1983-6. doi: 10.1097/00004872-199917121-00031. [PMID: 10703899]
  • H Negishi, K Ikeda, M Sagara, M Sawamura, Y Yamori. Increased oxidative DNA damage in stroke-prone spontaneously hypertensive rats. Clinical and experimental pharmacology & physiology. 1999 May; 26(5-6):482-4. doi: 10.1046/j.1440-1681.1999.03055.x. [PMID: 10386243]
  • T Kinugawa, M Kato, M Mori, A Endo, T Kato, T Hamada, N Noguchi, H Omodani, S Osaki, K Ogino, H Miyakoda, I Hisatome, C Shigemasa. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure. European journal of clinical pharmacology. 1998 May; 54(3):209-14. doi: 10.1007/s002280050447. [PMID: 9681661]
  • S Chen, Y Noguchi, T Izumida, J Tatebe, S Katayama. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. Journal of hypertension. 1996 Nov; 14(11):1325-30. doi: 10.1097/00004872-199611000-00011. [PMID: 8934361]
  • S Chen, H Kashiwabara, I Kosegawa, J Ishii, S Katayama. Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. Clinical and experimental hypertension (New York, N.Y. : 1993). 1996 Jul; 18(5):625-36. doi: 10.3109/10641969609081771. [PMID: 8781750]
  • T Murohara, S Tayama, T Tabuchi, H Sumida, T Honda, K Hayasaki, H Yasue. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. The American journal of cardiology. 1996 Jun; 77(14):1159-63. doi: 10.1016/s0002-9149(96)00155-5. [PMID: 8651088]
  • T Sato, Y Nara, Y Kato, Y Yamori. Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats. Metabolism: clinical and experimental. 1996 Apr; 45(4):457-62. doi: 10.1016/s0026-0495(96)90219-x. [PMID: 8609831]
  • B Cheung. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. British heart journal. 1995 Jun; 73(6):584-5. doi: 10.1136/hrt.73.6.584-b. [PMID: 7626365]
  • M Yoshimura, H Yasue, H Tanaka, K Kikuta, H Sumida, H Kato, M Jougasaki, K Nakao. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. British heart journal. 1994 Dec; 72(6):528-33. doi: 10.1136/hrt.72.6.528. [PMID: 7857734]
  • Y Uehara, N Hirawa, Y Kawabata, T Suzuki, N Ohshima, K Oka, T Ikeda, A Goto, T Toyo-oka, K Kizuki. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension (Dallas, Tex. : 1979). 1994 Dec; 24(6):770-8. doi: 10.1161/01.hyp.24.6.770. [PMID: 7995636]
  • K Itoh, S Yoshida, M Fukuda. The ACE inhibitor alacepril suppresses atherogenesis independent of serum lipids in cholesterol-fed rabbits--critical analysis with new ultrasound technique. Japanese circulation journal. 1994 Nov; 58(11):844-54. doi: 10.1253/jcj.58.844. [PMID: 7807684]
  • S Yoshida, K Itoh. High resolution miniature trans-esophageal echocardiography is useful to evaluate atherosclerosis and the effects of alacepril in hyper-cholesterol rabbits. Japanese heart journal. 1994 Nov; 35(6):789-9. doi: 10.1536/ihj.35.789. [PMID: 7897825]
  • N Hirawa, Y Uehara, Y Kawabata, N Ohshima, H Ono, T Nagata, T Gomi, T Ikeda, A Goto, S Yagi. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt-sensitive rats. Journal of hypertension. 1994 Aug; 12(8):909-18. doi: NULL. [PMID: 7814850]
  • M Saitoh, H Miyakoda, H Kitamura, T Kinugawa, H Kotake, H Mashiba. Effects of an angiotensin-converting enzyme inhibitor, alacepril, on cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension. Internal medicine (Tokyo, Japan). 1993 Sep; 32(9):691-4. doi: 10.2169/internalmedicine.32.691. [PMID: 8142672]
  • T Seta, S Fujii, M Nishizawa, U Miwa, H Nakabayashi, R Takeda. [The effect of alacepril on insulin sensitivity in patients with essential hypertension]. Nihon Naibunpi Gakkai zasshi. 1993 Mar; 69(3):158-65. doi: 10.1507/endocrine1927.69.3_158. [PMID: 8467930]
  • Y Takata, T Yoshizumi, Y Ito, M Ueno, A Tsukashima, M Iwase, K Kobayashi, M Fujishima. Comparison of withdrawing antihypertensive therapy between diuretics and angiotensin converting enzyme inhibitors in essential hypertensives. American heart journal. 1992 Dec; 124(6):1574-80. doi: 10.1016/0002-8703(92)90075-7. [PMID: 1462917]
  • T Kinugawa, H Kitamura, K Ogino, N Noguchi, T Matsumoto, I Hisatome, H Miyakoda, H Kotake, H Mashiba. Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension. British journal of clinical pharmacology. 1992 Oct; 34(4):366-9. doi: 10.1111/j.1365-2125.1992.tb05922.x. [PMID: 1457272]
  • K Tomita, H Nonoguchi, Y Terada, F Marumo. Renal effects of alacepril in essential hypertension. Journal of cardiovascular pharmacology. 1992 Oct; 20(4):520-4. doi: 10.1097/00005344-199210000-00002. [PMID: 1280705]
  • M Matsubara, Y Taguma, T Saito, K Yoshinaga. Anti-proteinuric and anti-coagulatory effects of camostat mesilate in azotemic diabetics. Nihon Jinzo Gakkai shi. 1992 Apr; 34(4):411-6. doi: NULL. [PMID: 1635286]
  • T Hashimoto. [Treatment of latent diabetic nephropathy with ACE inhibitor alacepril]. Nihon Jinzo Gakkai shi. 1991 Jun; 33(6):549-56. doi: NULL. [PMID: 1920934]
  • S Haisa, T Norii, E Takatori, A Goto, S Morioka, K Uchida, H Himei. Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria. The Journal of diabetic complications. 1991 Apr; 5(2-3):162-4. doi: 10.1016/0891-6632(91)90058-w. [PMID: 1770031]
  • K Utsunomiya, Y Ikeda. Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: an open multicenter trial. Alacepril Study Group. The Journal of diabetic complications. 1991 Apr; 5(2-3):165-6. doi: 10.1016/0891-6632(91)90059-x. [PMID: 1770032]
  • K Ohsawa, E Takazakura. Increased urinary excretion of kappa light chains in diabetic patients. The Journal of diabetic complications. 1991 Apr; 5(2-3):157. doi: 10.1016/0891-6632(91)90055-t. [PMID: 1770030]
  • M Ideishi, M Sasaguri, M Ikeda, K Arakawa. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension. Clinical therapeutics. 1989 Jul; 11(4):441-51. doi: NULL. [PMID: 2550133]
  • O Iimura, K Shimamoto. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives. Advances in experimental medicine and biology. 1989; 247A(?):39-48. doi: 10.1007/978-1-4615-9543-4_7. [PMID: 2532450]
  • S Tanaka, K Shimamoto, T Ando, Y Nakahashi, N Ura, S Hosoda, H Ishida, I Yamaji, T Yokoyama, A Masuda. Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alacepril. Clinical and experimental hypertension. Part A, Theory and practice. 1987; 9(2-3):605-9. doi: 10.3109/10641968709164231. [PMID: 3038424]
  • K Matsumoto, H Miyazaki, T Fujii, K Yoshida, H Amejima, M Hashimoto. Disposition and metabolism of the novel antihypertensive agent alacepril in rats. Arzneimittel-Forschung. 1986; 36(1):40-6. doi: NULL. [PMID: 3513776]
  • K Hosoki, K Takeyama, H Minato, F Fukuya, S Kawahara, T Kadokawa. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals. Arzneimittel-Forschung. 1986; 36(1):77-83. doi: NULL. [PMID: 3006712]
  • K Nambu, K Matsumoto, K Takeyama, K Hosoki, H Miyazaki, M Hashimoto. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats. Arzneimittel-Forschung. 1986; 36(1):47-51. doi: NULL. [PMID: 3006710]
  • K Takeyama, H Minato, K Nakatsuji, H Suzuki, I Nose, M Oka, K Hosoki, N Hatano, T Kadokawa. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals. Arzneimittel-Forschung. 1986; 36(1):69-73. doi: NULL. [PMID: 3513779]
  • K Onoyama, H Hirakata, H Tsuruda, N Ohchi, S Tomooka, K Motomura, T Omae, K Hayashi, M Fujishima. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. Clinical pharmacology and therapeutics. 1985 Oct; 38(4):462-8. doi: 10.1038/clpt.1985.205. [PMID: 3899460]
  • K Mizuno, S Hashimoto, N Kunii, M Tani, S Niimura, R Yabe, H Watari, S Fukuchi. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension. Research communications in chemical pathology and pharmacology. 1985 Aug; 49(2):175-87. doi: NULL. [PMID: 2997886]
  • K Takeyama, H Minato, F Fukuya, S Kawahara, K Hosoki, T Kadokawa. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs. Arzneimittel-Forschung. 1985; 35(10):1507-12. doi: NULL. [PMID: 3000390]
  • K Takeyama, H Minato, F Fukuya, S Kawahara, K Hosoki, T Kadokawa. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs. Arzneimittel-Forschung. 1985; 35(10):1502-7. doi: NULL. [PMID: 3000389]